Sucampo Re-Embraces Amitiza Through Co-Promote Option After Rescula Falters
This article was originally published in The Pink Sheet Daily
Executive Summary
While the company had been hopeful about diversifying its revenue base with the launch of its glaucoma drug Rescula, those hopes have faltered and pushed Sucampo to try to maximize the potential behind its main sales-driver, the constipation treatment Amitiza.